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Introduction
 
The World Health Organization began the Multinational
Project for Childhood Diabetes (DIAMOND) in 1990 [1]. Since
then, standardized incidence data on Type 1 diabetes have
been collected within the WHO DIAMOND Project until the
year 1999.
The report on incidence of childhood Type 1 diabetes from
1990 to 1994 showed even larger global variation in incidence
among children 
 
≤
 
 14 years of age than was reported previously
in the 1970s and 1980s [2–7]. During the first half of the
1990s, the overall age-adjusted incidence of Type 1 diabetes
varied from 0.1 in China and Venezuela to 37 per 100 000/
year in Sardinia and in Finland, representing a variation of
over 350-fold in the incidence in the 100 populations world-
wide. The variation in the incidence of Type 1 diabetes seemed
to reflect the global distribution of major ethnic populations
which demonstrate a different degree of genetic susceptibility
to diabetes. However, large differences in incidence have been
reported from European populations living in relatively close
proximity and in those who are genetically similar [8,9]. The
rapid increase in the incidence of Type 1 diabetes has been
almost a global phenomenon during the last decades [8,10].
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Abstract
 
Aims
 
To examine incidence and trends of Type 1 diabetes worldwide for the
period 1990–1999.
 
Methods
 
The incidence of Type 1 diabetes (per 100 000/year) was analysed in
children aged 
 
≤
 
 14 years from 114 populations in 112 centres in 57 countries.
Trends in the incidence of Type 1 diabetes were analysed by fitting Poisson
regression models to the dataset.
 
Results
 
A total of 43 013 cases were diagnosed in the study populations of
84 million children. The age-adjusted incidence of Type 1 diabetes among 112
centres (114 populations) varied from 0.1 per 100 000/year in China and Ven-
ezuela to 40.9 per 100 000/year in Finland. The average annual increase in incid-
ence calculated from 103 centres was 2.8% (95% CI 2.4–3.2%). During the
years 1990–1994, this increase was 2.4% (95% CI 1.3–3.4%) and during the
second study period of 1995–1999 it was slightly higher at 3.4% (95% CI 2.7–
4.3%). The trends estimated for continents showed statistically significant
increases all over the world (4.0% in Asia, 3.2% in Europe and 5.3% in North
America), except in Central America and the West Indies where the trend was a
decrease of 3.6%. Only among the European populations did the trend in incid-
ence diminish with age.
 
Conclusions
 
The rising incidence of Type 1 diabetes globally suggests the need
for continuous monitoring of incidence by using standardized methods in order
to plan or assess prevention strategies.
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In this study we investigated the age- and sex-specific incid-
ence of Type 1 diabetes and trends in incidence between 1990
and 1999 worldwide.
 
Materials and methods
 
The detailed plan and organizational structure of the WHO
DIAMOND incidence study have been described in previous
reports [1,2]. Each of the participating centres is headed by a
local principal investigator, who is responsible for data collec-
tion and the day-to-day aspects of the fieldwork (see Appen-
dix). To be eligible to participate in the WHO DIAMOND study
[1], each centre must have a well-defined population-based
registry where the incidence can be accurately ascertained.
Every centre prepared its own local methods of operation
for the incidence study by following the framework provided
by the WHO DIAMOND incidence study. In the local methods
of operation, centres described the population base, the design
of the registry, sources of data, data management, data items,
and the time schedule for data collection. This analysis in-
cludes 112 centres from 57 countries. Most European coun-
tries included in the DIAMOND study are members of the
EURODIAB Study Group [6].
 
Incidence study population
 
The total number of children aged 14 years or under living in
the countries collaborating in the WHO DIAMOND incidence
study was 740 million in 1996. The denominator for the ana-
lyses which included the children 
 
≤
 
 14 years of age who resided
in the study areas averaged 84 million per year. The numerator
comprises 43 013 children 
 
≤
 
 14 years of age diagnosed with
Type 1 diabetes between the years 1990 and 1999 in the study
areas.
 
Classification and case definition
 
The 1985 WHO classification of diabetes and the diagnostic
criteria [11] are the basis of the minimum set of criteria for the
WHO DIAMOND incidence study. Eligible individuals began
daily insulin injections before their 15th birthday and were
resident in the area of registration at the time of the first insulin
administration. Registries are either prospective, retrospective
or a combination of both. Participating centres have submitted
annual incidence data to the WHO DIAMOND data centre
in Helsinki using standardized forms. Data on gender, ethnic
group, date of birth, date of first insulin administration, source
of data (primary, secondary), family history of diabetes (the
diabetic status of siblings, parents and children of registered
cases) are collected
 
.
 
 All the cases included in the database must
have data at least on gender, the date of birth and the date of
first insulin administration.
Completeness of registration was confirmed by estimating
the degree of ascertainment using the capture–recapture method
[12] in most centres. In some centres (see Fig. 1) this was not
necessary as a result of complete coverage of the primary
source. According to the WHO DIAMOND methods of opera-
tion, the primary data source consists of the cases of Type 1
diabetes who fulfil the criteria for registration and have been
identified from hospital records, or from the records of paedia-
trician or family physician. Records of the local diabetes asso-
ciation, school health records or social insurance schemes have
been used as a secondary (independent) source for cases.
 
Statistical methods
 
Incidence rates were calculated as the incidence per calendar
year and 100 000 population at risk without adjustment for
under-reporting. Age adjustment for the rates was carried out
using the direct method with a standard population consisting of
equal numbers of children in each of the three age groups (0–4,
5–9, 10–14 years of age). The 95% confidence intervals were
estimated assuming the Poisson distribution of the cases. The
incidence rates were divided into five groups, as in our earlier
report: (i) very low, < 1 per 100 000/year; (ii) low, 1–4.99 per
100 000/year; (iii) intermediate, 5–9.99 per 100 000/year; (iv)
high, 10–19.99 per 100 000/year, and (v) very high, 
 
≥
 
 20 per
100 000/year [2].
Poisson regression models were used to analyse the incidence
rates by centre, gender, age, and calendar year, and their inter-
actions. Models were fitted using the S-PLUS.
 
Results
 
Incidence of Type 1 diabetes
 
During the period 1990–1999, the overall age-adjusted incid-
ence of Type 1 diabetes in 112 centres (114 populations) varied
from 0.1/100 000/year in China and Venezuela to 40.9 per
100 000/year in Finland (Table 1, Fig. 1). In most Asian popu-
lations the incidence was very low; 70% of them having an
incidence of < 1 per 100 000/year. A marked exception among
the Asian populations was Kuwait, with a very high incid-
ence of 22 per 100 000/year. Among African populations,
incidence was low or intermediate, ranging between 1 per
100 000/year and 9 per 100 000/year. The incidence among
South American populations varied between very low to high,
< 1 per 100 000/year to 10 per 100 000/year. In Central Amer-
ica and the West Indies, the range of variation was from 2 per
100 000/year to 17 per 100 000/year. The highest incidence
rates were among European and North American populations
varying from low, 4 per 100 000/year, to very high, 41 per 100
00/year, in Europe and from high, 11 per 100 000/year, to very
high, 25 per 100 000/year, in North America. In Oceania, the
incidence of Type 1 diabetes was also high or very high, rang-
ing from 14 per 100 000/year to 22 per 100 000/year, reflect-
ing difference in the ethnicity of populations within this region.
There was also a marked within-country variation in the age-
adjusted incidence in most of countries having data from at
least two centres (Table 1).
 
Age and sex differences in incidence
 
The age-specific incidence rates were calculated for three age
groups (0–4, 5–9 and 10–14 years) separately for boys and
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girls On the whole, there were no marked differences in age-
group specific incidence between the genders. The differences
in incidence rates between age groups were statistically signif-
icant (
 
P <
 
 0.001) in almost all countries. In general, the incid-
ence increased with age (Table 2). In the pooled data, the
5–9-year olds had 1.62 (1.57–1.66) times higher risk, and the
10–14-year olds 1.94 (1.89–1.98) times higher risk than that
of the 0–4-year olds. The effect of age on the incidence did not
differ between the genders. The exceptions were two countries
of very high incidence, namely Finland and Sweden, and two
countries with intermediate incidence, i.e. Romania and
Lithuania. In all these countries, the age-specific incidence
rates increased from 0 to 4 years to 10–14 years among boys,
whereas among girls incidence increased only from the age
group 0–4 years to the ages 5–9 years.
 
The global trend in the incidence of Type 1 diabetes
 
The mean annual increase in incidence calculated from
103 centres (submitted data for 3 years or more) was 2.8%
(95% CI 2.4–3.2%; Table 3). In the first 5-year study
from 1990 to 1994, the average annual increase was 2.4%
(1.3–3.4%). During the second study period from 1995 to
1999, the annual increase was higher at 3.4% (2.7–4.3%),
but the difference in the trend between periods was not
statistically significant.
The trend in incidence did not differ significantly between
genders, except in Kuwait, Bulgaria, and Cuba. In Kuwait, the
annual increase was 2.9% (
 
−
 
2.4 to 8.6%) in boys and 11.2%
(5.4–17.4%) in girls, in Bulgaria there was an increase of 7.5%
(4.2–10.8%) in boys and an increase of 2.4% (
 
−
 
0.9 to 5.9%)
Figure 1 Age-standardized incidence of Type 1 
diabetes in children under 14 years of age (per 
100 000 per year). Countries are arranged in 
descending order according to the incidence.
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Table 1
 
Age-standardized incidence of Type 1 diabetes in children aged 14 years or under (per 100 000/year)
 
 
 
Region Country and area Study period
Estimate of 
ascertainment %
Incidence
Boys/girls
Annual change 
of incidence
Boys Girls Total (95% CI) % (95% CI)
 
Africa
 
3.0 (0.3; 5.8)
Algeria 11.6 (5.5; 18.0)
Oran* 1990–1999 7.7 9.6 8.6 (7.6; 9.8) 0.8
Libya
 
−
 
0.9 (
 
−
 
5.6; 4.0)
Benghazi 1991–1999 7.8 10.3 9.0 (8.0; 10.2) 0.8
Mauritius 1990–1994 35–100 1.2 1.4 1.3 (0.8; 2.0) 0.9
 
−
 
2.2 (
 
−
 
27.8; 32.3)
Sudan
Gezira 1990 100 5.6 4.4 5.0 (3.8; 6.5) 1.3
Tunisia 0.7 (
 
−
 
3.5; 5.2)
Beja* 1990–1999 8.4 6.9 7.7 (6.1; 9.6) 1.2
Gafsa* 1990–1999 9.5 7.5 8.5 (6.9; 10.3) 1.3
Kairoan* 1991–1993 7.3 7.8 7.6 (5.6; 10.0) 0.9
Monastir* 1990–1999 6.6 5.1 5.8 (4.6; 7.3) 1.3
 
Asia
 
4.0 (1.8; 6.2)
China
 
−
 
0.1 (
 
−
 
5.7; 5.8)
Beijing* 1990–1994 0.7 1.1 0.9 (0.7; 1.1) 0.6†
Chang Chun 1990–1994 86–100 0.6 1.1 0.8 (0.5; 1.3) 0.6
Changsha 1990–1994 100 0.2 0.2 0.2 (0.2; 0.4) 1.3
Dalian 1990–1994 100 1.1 1.2 1.2 (0.7; 1.7) 0.9
Guilin 1991–1994 100 0.6 1.0 0.8 (0.2; 2.0) 0.6
Hainan 1990–1994 100 0.1 0.2 0.2 (0.1; 0.2) 0.5
Harbin 1990–1996 100 0.6 0.6 0.6 (0.4; 0.8) 1.0
Hong-Kong* 1990–1995 0.6 1.9 1.3 (0.8; 1.9) 0.3†
Huhehot 1990–1994 100 1.1 0.7 0.9 (0.5; 1.5) 1.5
Jilin 1990–1994 100 0.4 0.8 0.6 (0.4; 0.9) 0.5
Jinan 1990–1995 100 0.5 0.4 0.4 (0.3; 0.6) 1.1
Lanzhou 1991–1994 100 0.4 0.2 0.3 (0.1; 0.5) 1.9
Nanjing 1990–1995 100 0.5 1.2 0.9 (0.6; 1.2) 0.5
Nanning 1990–1994 100 0.3 0.7 0.5 (0.3; 0.8) 0.4
Shanghai 1990–1994 69–100 0.7 0.7 0.7 (0.5; 0.9) 0.9
Shenyang 1990–1994 100 0.4 0.5 0.5 (0.3; 0.7) 0.9
Sichuan 1990–1994 80–100 1.8 2.7 2.3 (1.4; 3.3) 0.7
Tie Ling 1990–1994 100 0.2 0.1 0.2 (0.1; 0.3) 1.0
Wuhan 1990–1994 100 5.2 3.8 4.5 (2.8; 7.0) 1.5
Wulumuqi 1990–1994 100 0.9 0.8 0.8 (0.3; 1.7) 1.2
Zhengzhou 1991–1994 86–100 0.2 1.0 0.6 (0.3; 1.1) 0.2
Zunyi 1990–1995 100 0.0 0.1 0.1 (0.0; 0.2) 0.6
Israel‡ 1990–1993 100 5.5 6.6 6.0 (5.4; 6.7) 0.8† 7.6 (
 
−
 
2.0; 18.1)
Japan
 
−
 
3.5 (
 
−
 
15.7; 10.6)
Chiba* 1990–1993 1.2 1.6 1.4 (1.1; 1.8) 0.8
Hokkaido 1990–1993 100 2.2 2.1 2.2 (1.7; 2.6) 1.0
Okinawa 1990–1993 77–100 1.0 1.8 1.4 (0.8; 2.2) 0.6
Kuwait 1992–1999 79–96 21.7 22.9 22.3 (20.5; 24.2) 1.0 7.0 (3.0; 11.1)
Pakistan
 
−
 
5.6 (
 
−
 
11.2; 0.3)
Karachi 1990–1999 51 0.4 0.5 0.5 (0.3; 0.5) 0.8
Russia 6.6 (3.0; 10.3)
Novosibirsk 1990–1999 87–100 6.8 7.1 6.9 (6.3; 7.6) 1.0
South Korea
Seoul* 1990–1991 1.1 1.2 1.1 (0.9; 1.5) 0.9
 
Europe
 
3.2 (2.7; 3.6)
Austria‡ 1990–1999 99–100 10.3 9.5 9.9 (9.4; 10.4) 1.1 2.1 (
 
−
 
0.4; 4.8)
Belgium‡ 1.5 (
 
−
 
3.4; 6.7)
Antwerpen 1990–1999 90–100 10.7 12.8 11.7 (10.2; 13.5) 0.8
Bulgaria 5.1 (2.8; 7.5)
Varna 1990–1999 100 7.9 8.3 8.1 (7.4; 9.0) 1.0
West-Bulgaria 1990–1999 99–100 11.6 9.8 10.7 (9.8; 11.6) 1.2†
Czech Republic‡ 1995–1999 12.6 12.7 12.7 (11.9; 13.5) 1.0 9.6 (5.2; 14.2)
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Denmark‡ 15 (
 
−
 
2.6; 5.7)
Four counties 1990–1999 83–100 17.1 16.2 16.6 (14.9; 18.4) 1.1
Estonia* 1990–1999 12.6 10.9 11.7 (10.6; 13.0) 1.1 3.7 (0.1; 7.5)
Finland* 1990–1999 41.9 39.9 40.9 (39.6; 42.2) 1.1† 4.2 (3.1; 5.3)
France‡ 4.8 (
 
−
 
0.5; 10.5)
Four regions 1990–1994 95–99 8.7 8.3 8.5 (7.9; 9.1) 1.1
FYR Macedonia‡ 1995–1999 4.9 3.5 4.2 (3.4; 5.2) 1.4 9.7 (
 
−
 
9.6; 33.2)
Germany‡ 2.3 (0.8; 3.8)
Düsseldorf 1995–1999 97–98 14.8 16.1 15.4 (13.8; 17.2) 0.9
Baden-Württemberg 1990–1999 91–100 12.7 12.6 12.6 (12.1; 13.2) 1.0
Greece‡ 0.9 (
 
−
 
2.0; 3.8)
Attica 1990–1999 100 11.0 9.0 10.0 (9.2; 10.9) 1.2†
Hungary‡ 2.6 (0.8; 4.5)
Eighteen counties 1990–1999 99–100 9.6 9.8 9.7 (9.2; 10.2) 1.0
Italy 0.9§ (
 
−
 
0.9; 2.7)
Lazio‡* 1990–1999 8.9 8.6 8.8 (8.1; 9.4) 1.0
Lombardia‡ 1990–1995 100 7.2 6.5 6.9 (6.3; 7.5) 1.1
Marche 1990–1999 100 10.5 9.7 10.1 (8.8; 11.6) 1.1
Pavia 1990–1999 100 12.3 12.5 12.4 (9.7; 15.6) 1.0
Sardinia‡ 1990–1998 37–85 45.0 30.6 37.8 (35.5; 40.3) 1.5 1.4 (
 
−
 
1.1; 3.9)
Eastern Sicily‡ 1990–1994 96–100 13.4 9.9 11.7 (9.8; 13.9) 1.3
Turin 1990–1999 97–100 11.7 10.3 11.0 (9.8; 12.3) 1.1
Latvia 1990–1999 7.8 7.0 7.4 (6.6; 8.3) 1.1 3.1 (
 
−
 
0.6; 6.8)
Lithuania 1990–1999 100 7.6 8.2 7.9 (7.3; 8.5) 0.9 2.5 (
 
−
 
0.2; 5.3)
Luxemburg‡ 1990–1999 100 10.3 12.2 11.3 (9.0; 13.9) 0.8
 
−
 
0.1 (
 
−
 
7.2; 8.1)
The Netherlands‡ 3.4 (
 
−
 
4.0; 11.3)
Five regions 1990–1994 87–98 12.9 13.2 13.0 (11.7; 14.4) 1.0
Norway‡
 
−
 
0.9 (
 
−
 
3.2; 1.4)
Eight counties 1990–1999 91–100 21.6 19.9 20.8 (19.4; 22.1) 1.1
Poland 7.6 (4.9; 10.4)
Cracow* 1990–1999 100 7.5 7.6 7.6 (7.0; 8.2) 1.0
Upper Silesia‡ 1995–1999 8.0 9.5 8.8 (7.9; 9.7) 0.8
Wielkopolska 1990 100 4.1 6.0 5.0 (3.9; 6.4) 0.7
Portugal 2.0 (
 
−
 
4.1; 8.4)
Algarve‡ 1990–1994 74–100 16.3 12.9 14.6 (10.6; 19.6) 1.3
Coimbra 1990–1999 100 10.1 9.1 9.6 (7.6; 12.2) 1.1
Madeira Island‡ 1990–1999 100 7.1 6.8 6.9 (5.0; 9.4) 1.1
Portalegre‡ 1990–1994 86–100 15.9 26.7 21.3 (13.3; 31.9) 0.6
Romania‡ 2.8 (
 
−
 
3.9; 10.0)
Bucharest 1990–1999 100 4.7 5.9 5.3 (4.7; 6.1) 0.8
Slovakia 1990–1999 100 9.7 9.7 9.7 (9.2; 10.3) 1.0 6.3 (4.3; 8.5)
Slovenia‡ 1990–1999 100 8.3 9.5 8.9 (8.0; 9.9) 0.9 3.3 (
 
−
 
0.5; 7.2)
Spain
 
−
 
1.9 (
 
−
 
3.7; 0.0)
Catalonia 1990–1999 50–96 12.6 12.3 12.4 (11.7; 13.1) 1.0
Sweden* 1990–1999 100 30.5 29.4 30.0 (29.1; 30.8) 1.0 3.6 (2.6; 4.7)
Switzerland‡ 1995–1999 13.3 10.7 12.0 (11.2; 12.9) 1.2† 2.1 (
 
−
 
3.1; 7.5)
UK 4.0 (3.0; 5.0)
Scotland (Aberdeen) 1990–1999 100 26.8 25.9 26.4 (25.4; 27.4) 1.0
Leicestershire‡ 1990–1994 97–100 15.4 15.3 15.3 (12.9; 18.1) 1.0
Northern Ireland‡ 1990–1999 95–100 21.5 21.2 21.3 (19.9; 22.8) 1.0
Oxford‡* 1990–1994 20.1 15.3 17.7 (16.2; 19.5) 1.3†
Plymouth 1990–1999 96–100 17.1 20.8 19.0 (16.8; 21.2) 0.9
Yorkshire‡ 1990–1999 99 18.9 18.1 18.5 (17.5; 19.5) 1.0
 
North America
 
5.3 (3.3; 7.3)
Canada 5.1 (1.9; 8.5)
Edmonton 1990–1996 75–96 23.0 23.6 23.3 (20.5; 26.4) 1.0
Calgary 1990–1999 100 20.3 20.9 20.6 (18.5; 22.7) 1.0
Prince Edward Island* 1990–1993 100 28.0 20.8 24.5 (16.4; 35.2) 1.3
Region Country and area Study period
Estimate of 
ascertainment %
Incidence
Boys/girls
Annual change 
of incidence
Boys Girls Total (95% CI) % (95% CI)
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USA 5.5 (3.0; 8.0)
Allegheny, PA 1990–1994 87–100 19.1 16.4 17.8 (15.5; 20.3) 1.2
Chicago, IL
African-American 1990–1999 51–100 15.2 19.4 17.3 (15.8; 18.7) 0.8†
Hispanic 1990–1999 51–100 11.7 11.1 11.4 (10.1; 12.9) 1.1
Others 1995–1999 > 75 19.0 17.5 18.3 (15.7; 22.2) 1.1
Jefferson, AL* 1990–1995 14.1 15.1 14.6 (12.2; 18.2) 0.9
 
South America
 
5.3 (2.8; 7.9)
Argentina 0.4 (
 
−
 
8.8; 10.5)
Avellaneda 1990–1996 88–100 5.3 7.2 6.3 (5.7; 11.1) 0.7
Cordoba 1991–1992 88–92 6.2 7.9 7.0 (5.2; 9.3) 0.8
Corrientes 1992–1999 90–100 4.7 8.5 6.6 (5.0; 8.7) 0.6
Tierra del Fuego 1993–1996 100 14.2 6.3 10.3 (5.5; 18.5) 2.2
Brazil
 
−
 
16.0 (
 
−
 
48.6; 37.2)
Sao Paulo 1990–1992 70–95 6.9 9.1 8.0 (5.5; 11.1) 0.8
Passo Fundo 1996–1999 100 5.4 8.7 7.0 (4.1; 11.9) 0.6
Chile 7.5 (4.3; 10.9)
Santiago 1990–1999 100 3.6 3.9 3.7 (3.4; 4.0) 0.9
Colombia
Cali* 1995–1999 0.4 0.5 0.5 (0.3; 0.7) 0.8
Bogota 1990 97 4.7 2.9 3.8 (2.9; 4.9) 1.6
Paraguay* 1990–1999 1.0 0.8 0.9 (0.8; 1.0) 1.1
 
−
 
0.5 (
 
−
 
5.7; 4.9)
Peru 12.1 (
 
−
 
7.5; 35.8)
Lima 1990–1994 35–100 0.4 0.6 0.5 (0.4; 0.64) 0.7
Uruguay
Montevideo 1992 97 8.3 8.2 8.3 (5.4; 11.7) 1.0
Venezuela
 
−
 
6.8 (
 
−
 
24.6; 15.3)
Caracas* 1990–1994 0.1 0.2 0.1 (0.1; 0.2) 0.7
 
Central America and West 
Indies
 
−
 
3.6 (
 
−
 
5.0; 
 
−
 
2.2)
Barbados* 1990–1993 2.4 1.6 2.0 (0.6; 4.1) 1.5
Cuba 1990–1999 25–100 2.1 2.5 2.3 (2.2; 2.5) 0.8
 
−
 
10.8 (
 
−
 
13.4; 
 
−
 
8.2)
Dominica 1990–1993 6.6 4.9 5.7 (2.4; 12.6) 1.3
 
−
 
46.1 (
 
−
 
78.3; 34.0)
Dominican Republic 1995–1999 39–67 0.7 0.3 0.5 (0.4; 0.7) 2.3† 12.6 (
 
−
 
11.4; 43.0)
Mexico
Veracruz 1990–1993 100 1.5 (0.7; 2.9)
Puerto Rico (USA) 1990–1999 90–97 15.8 17.8 16.8 (16.0; 17.6) 0.9†
 
−
 
1.0 (
 
−
 
2.7; 0.7)
Virgin Islands (USA)* 1990–1996 14.0 12.8 (8.1; 18.8) 7.1 (
 
−
 
13.2; 32.1)
 
Oceania
 
3.2 (
 
−
 
0.4; 6.9)
Australia 4.1 (
 
−
 
2.5; 11.1)
New South Wales 1990–1993 89–100 13.1 15.9 14.5 (13.5; 15.6) 0.8†
New Zealand 2.8 (
 
−
 
1.4; 7.2)
Auckland 1990–1996 100 12.9 14.6 13.7 (12.0; 15.7) 0.9
Canterbury 1990–1999 100 23.8 20.8 22.3 (19.1; 25.9) 1.1
*One source.
†Statistically significant 
 
P
 
 < 0.05.
‡Also belongs to EURODIAB Ace Study.
§Without Sardinia.
Region Country and area Study period
Estimate of 
ascertainment %
Incidence
Boys/girls
Annual change 
of incidence
Boys Girls Total (95% CI) % (95% CI)
 
Table 1
 
Continued
 
in girls, and in Cuba a decrease of 7.4% (3.5–11.3%) in boys
and a decrease of 13.9% (10.3–17.4%) in girls.
In the pooled data, the increase was less in the older age
groups: 4.0% (3.1–4.9%) in the 0–4-year age group, 3.0%
(2.4–3.7%) in the 5–9-year age group and 2.1% (1.5–2.7%) in
the 10–14-year age group. This decrease in the annual increase
over the age groups was seen mainly in European populations.
The trend was also estimated by continents (Table 3). The
statistically significant increasing trend was 4.0% (1.8–6.2%)
in Asia, 3.2% (2.7–3.6%) in Europe and 5.3% (3.3–7.3%) in
North America. In Central America and the West Indies, the
trend was a significant decrease at 3.6% (2.2–5.0%). How-
ever, a decreasing trend in this area was seen only in Cuba
where the decrease was 10.8% (Table 1). In general, the
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increasing trend was strongest in the centres with very high
incidence 3.7% (3.1–4.2%) and in centres with intermediate
incidence 3.5% (2.8–4.2%). In the centres with low and very
low incidence, there were no significant increases in incidence
rates over time.
When Poisson regression models were fitted to the dataset
(Table 4), the simplest model showed that there were statisti-
cally significant differences in incidence between centres and
age groups, but not between genders (Table 4, lines 2, 4 and
3). The overall annual increase in incidence was statistically
significant (line 5) and the effect of age and gender on the incid-
ence was not similar in all centres (lines 6, 7 and 12). The
trends in incidence varied between the age groups (line 11) and
between centres (line 9).
 
Discussion
 
The rising incidence of Type 1 diabetes is a global pheno-
menon. The incidence of Type 1 diabetes has increased by
2.8% per year during the years 1990–1999 worldwide. Thus,
the results of this study confirm the previously reported trend of
2.5–3.0% annual increase in incidence since the early 1970s
[8,10]. The total population of children aged 14 years or under
(740 million) from countries for which the incidence of Type 1
diabetes is estimated using a standardized study protocol cov-
ers 41% of the world’s population aged 14 years or under. The
global variation in incidence (> 350-fold) appears to be stable,
although we were not able to estimate the global range for the
whole 10-year study period, because incidence data from most
low incidence countries were available for the first 5-year
period only. There was also within-country variation in inci-
dence in several countries. However, it has not been possible to
investigate this variation further in this review.
The global increase in incidence of Type 1 diabetes may be
partly explained by an improvement in case ascertainment. An
underestimation is certainly inherent in all registration sys-
tems, but the problem was avoided in this study by measuring
the degree of ascertainment on the basis of two or more data
sources. In some countries collecting incidence data, secondary
sources for ascertainment of cases are not available or are dif-
ficult to find. However, 81% of registries checked the degree
of ascertainment using two independent data sources. Most of
the information of the incidence of Type 1 diabetes is from
regions with a high or intermediate incidence, mostly in
Europe and North America, where several registries have been
established since the mid-1980s or even before. The data from
Asia, South America and Africa are still sparse. However, the
incidence appears to be increasing in almost all populations
worldwide and statistically significant increases were found in
all continents except in South America, Central America and
the West Indies. The latter was the only continent where there
was a significantly decreasing trend in this study.
Unfortunately, information is lacking from many countries
with very low gross domestic product and the largest child
populations. These are mostly countries in Africa and South
and East Asia, where infectious diseases are the greatest child-
hood killers. When one child in 10 dies before his/her fifth
birthday, as happens in these countries today, it may be prac-
tically impossible to get reliable data on the incidence of dia-
betes among children. The symptoms of diabetes surely remain
Table 2 Poisson regression analyses of the incidence of Type 1 diabetes 
in age groups by sex (pooled analyses for all centres)
 
 
Age group (years) Risk ratio 95% CI
Boys* 0–4 1.00
5–9 1.52 (1.47; 1.58)
10–14 1.94 (1.87; 2.01)
Girls* 0–4 1.00
5–9 1.72 (1.66; 1.79)
10–14 1.93 (1.86; 2.01)
Total† 0–4 1.00
5–9 1.62 (1.57; 1.66)
10–14 1.94 (1.89; 1.98)
*Adjusted for centre.
‡Adjusted for centre and sex.
Table 3 Annual increase (%) of incidence of Type 1 diabetes by age groups and by continents in children aged 14 or under in 1990–1999; the results 
of the Poisson regression analyses
 
 
Continent
Total Age/ year* 0–4 years 5–9 years 10–14 years
 PTrend % 95% CI P Trend % 95% CI Trend % 95% CI Trend % 95% CI
Africa 3.0 (0.3; 5.8) 0.029 0.9 (−5.6; 7.9) 9.2 (3.8; 14.9) 0.6 (−3.0; 4.3) 0.154
Asia 4.0 (1.8; 6.2) <0.001 1.3 (−3.5; 6.2) 5.0 (1.4; 8.8) 5.1 (1.8; 8.5) 0.238
Europe 3.2 (2.7; 3.6) <0.001 4.7 (3.9; 5.6) 3.4 (2.7; 4.0) 2.2 (1.6; 2.8) <0.001
North America 5.3 (3.3; 7.3) <0.001 6.9 (2.4; 11.5) 4.7 (1.4; 8.1) 5.1 (2.3; 8.1) 0.674
South America 5.3 (2.8; 7.9) <0.001 6.5 (1.2; 12.0) 9.2 (4.7; 13.9) 1.7 (−2.0; 5.6) 0.071
Central America and West Indies −3.6 (−5.0; −2.2) <0.001 −3.6 (−6.7; 0.3) −4.2 (−6.5; −1.9) −3.2 (−5.3; 1.0) 0.881
Oceania 3.2 (−0.4; 6.9) <0.001 11.1 (3.2; 19.6) −0.6 (−6.4; 5.5) 2.1 (−3.3; 7.8) 0.042
All regions 2.8 (2.4; 3.2) <0.001 4.0 (3.1; 4.9) 3.0 (2.4; 3.7) 2.1 (1.5; 2.7) <0.001
*Interaction between age group and calendar year.
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unrecognized when children die, for example, from acute
respiratory infections or diarrhoea. Thus, reliable estimation
of the incidence of diabetes in these areas may be possible only
after child mortality decreases.
The risk of Type 1 diabetes has been increasing since the
1950s and there are no signs that this trend is abating
[8,10,13]. The results of this analysis confirm the widely
believed assumption that the increase in the incidence of
Type 1 diabetes has been very rapid, particularly in the young-
est age groups in European populations [14–18]. Another
widely adopted assumption that high incidence regions, except
Finland, would have reached a plateau is not supported by our
analysis. We found no significant differences in the trend of
incidence levels over time between participating countries.
The constantly increasing incidence of Type 1 diabetes over
such a short period of time (10 years) cannot be explained by
shifts in genetic susceptibility alone. Hence, causative agents
should be sought in the environment or in gene–environment
interaction. There is already some evidence that rapid growth
and obesity in early childhood increases the risk of Type 1 dia-
betes [19]. Further, psychological stress in families has been
found to be associated with diabetes-associated autoanti-
bodies in 1-year-old children [20]. Recent studies [21–24] have
shown that environmental factors have a stronger effect on
genetically non-susceptible individuals than those genetically
susceptible to getting Type 1 diabetes. It might be timely to
extend the study of the environmental agents to completely
new areas of children’s lifestyle, including social circumstances,
stressful life events, and health behaviour in the widest sense.
In conclusion, the incidence of childhood Type 1 diabetes
continues to rise and continuous monitoring, using updated
diagnostic criteria and developed standardized methods, is
required. In particular, it is important to differentiate between
Type 1 and Type 2 diabetes, because the latter has become
increasingly common in adolescents in some populations
The fact that prevention strategies are presently in progress
justifies ongoing surveillance of incidence: i.e. when these trials
are performed on a population basis, surveillance will allow us
to demonstrate their effectiveness.
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